The stock of Galectin Therapeutics Inc (GALT) has gone up by 56.07% for the week, with a 79.33% rise in the past month and a 124.70% rise in the past quarter. The volatility ratio for the week is 15.98%, and the volatility levels for the past 30 days are 8.54% for GALT. The simple moving average for the past 20 days is 63.06% for GALT’s stock, with a 104.60% simple moving average for the past 200 days.
Is It Worth Investing in Galectin Therapeutics Inc (NASDAQ: GALT) Right Now?
Moreover, the 36-month beta value for GALT is 0.83. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GALT is 42.38M and currently, short sellers hold a 5.06% of that float. On April 08, 2024, GALT’s average trading volume was 82.97K shares.
GALT) stock’s latest price update
The stock of Galectin Therapeutics Inc (NASDAQ: GALT) has increased by 24.33 when compared to last closing price of 3.00.Despite this, the company has seen a gain of 56.07% in its stock price over the last five trading days. InvestorPlace reported 2024-04-05 that Galectin Therapeutics (NASDAQ: GALT ) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents.
Analysts’ Opinion of GALT
Many brokerage firms have already submitted their reports for GALT stocks, with H.C. Wainwright repeating the rating for GALT by listing it as a “Buy.” The predicted price for GALT in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on August 13, 2020 of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see GALT reach a price target of $11. The rating they have provided for GALT stocks is “Buy” according to the report published on February 13th, 2019.
H.C. Wainwright gave a rating of “Buy” to GALT, setting the target price at $10 in the report published on December 07th of the previous year.
GALT Trading at 87.22% from the 50-Day Moving Average
After a stumble in the market that brought GALT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 24.33% of gains for the given period.
Volatility was left at 8.54%, however, over the last 30 days, the volatility rate increased by 15.98%, as shares surge +78.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +116.86% upper at present.
During the last 5 trading sessions, GALT rose by +56.07%, which changed the moving average for the period of 200-days by +162.68% in comparison to the 20-day moving average, which settled at $2.37. In addition, Galectin Therapeutics Inc saw 124.70% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GALT starting from ELDRED KARY, who purchase 500 shares at the price of $1.79 back on Jan 16 ’24. After this action, ELDRED KARY now owns 49,313 shares of Galectin Therapeutics Inc, valued at $893 using the latest closing price.
ELDRED KARY, the Director of Galectin Therapeutics Inc, purchase 1,598 shares at $1.79 during a trade that took place back on Jul 19 ’23, which means that ELDRED KARY is holding 48,813 shares at $2,854 based on the most recent closing price.
Stock Fundamentals for GALT
The total capital return value is set at -3.04.
Based on Galectin Therapeutics Inc (GALT), the company’s capital structure generated 6.22 points at debt to capital in total, while cash flow to debt ratio is standing at -0.46. The debt to equity ratio resting at -1.19. The interest coverage ratio of the stock is -13.64.
Currently, EBITDA for the company is -38.04 million with net debt to EBITDA at -1.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
To wrap up, the performance of Galectin Therapeutics Inc (GALT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
